Loading stock data…
uniQure N.V. (QURE)
$45.68+1.18 (+2.65%)
Market ClosedLast close Sep 8
uniQure N.V.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
uniQure N.V. in the Healthcare sector is trading at $45.68 with a market capitalization of $3.4B. Wall Street consensus targets $69.78 (12 analysts), implying a +52.7% move over the next 12 months. The stock is currently 36% below its 52-week high of $71.50, remaining 60.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +52.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.84M↑ | $3.56M↓ | $5.57M↑ | $3.70M↓ | $5.26M |
| Gross Profit | $5.49M↑ | $3.34M↓ | $5.13M↑ | $3.30M↓ | $4.61M |
| Operating Income | -$44.68M↓ | -$44.27M↑ | -$51.49M↓ | -$49.49M↓ | -$42.88M |
| Net Income | -$81.06M↓ | -$53.53M↓ | -$37.09M↑ | -$80.53M↓ | -$37.72M |
Peer Comparison
JNJUNHPFE
Fundamentals
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.37B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-77.83%
Volume
Today's trading volume
1.35M
Recent News
ClearPoint Neuro (CLPT) Stock Sees Fair Value Cut As Analysts Factor In Heavier Investment
Price targets for ClearPoint Neuro have shifted toward the low to mid US$20s, with the average assessed fair value moving from US$28.33 to US$23.50 and one outlier still at US$30. Analysts link this change to a period they see as more investment heavy, balancing optimism about long term growth potential with caution around near term execution and partner related contributions. As you read on, you will see how this evolving narrative could shape the way you track ClearPoint Neuro from...
uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval
After a very large three year gain in uniQure’s share price, the stock now screens as overvalued on market multiples and carries a mixed overall value score rather than a clear bargain signal. The recent run and the current valuation checks give investors a more finely balanced picture. Over the past three years, uniQure has returned very close to 7x for shareholders, which places extra focus on how much of the company’s future potential is already priced in. The recent Biologics License...
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QURE Submits Application for Gene Therapy for Huntington's Disease
QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.
QURE Stock Fades After AMT-130 filing — But William Blair Sees 58% Upside
uniQure announced it had submitted a Biologics License Application to the FDA seeking accelerated approval of ifezuntirgene inilparvovec, or AMT-130, for Huntington’s disease.